In the first of a two-part interview with Cannabiz, Cann Group chief operating officer Shane Duncan reveals how the company’s new acquisition could unlock unique opportunities.

Victims of cybercrime, a revenue downgrade, a fluctuating share price and a trading halt triggered by an administrative blunder.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

It’s been a far from serene February for Cann Group.

Cann’ Group’s acquisition of Satipharm could accelerate registration of an S3 over-the-counter product in Australia

The month started with the cyber theft, which saw $3.6m vanish into the underworld of online crime.

An investigation has yet to be concluded, but it seems unlikely Cann will recover the funds, which had been destined for a Dutch-based contractor.

The revenue downgrade, meanwhile, which cut Cann’s $15m target by at least one third, was blamed on health regulators’ preoccupation with Covid, their other tasks relegated to the back of an ever-lengthening queue.

Understandable as that may be, missing targets, regardless of the reason, can make investors edgy.

As for Monday’s enforced trading halt, an “inadvertent administrative oversight” was blamed for a failure to lodge correct paperwork relating to a shares issue. A minor infringement in the grand scheme of things, but the ASX takes a dim view of such procedural errors.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...